Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I First-in-Human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination With Durvaluamb (MEDI4736) in Participants With Advanced Solid Tumours.

NCT04504669 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04504669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04504669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I First-in-Human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination With Durvaluamb (MEDI4736) in Participants With Advanced Solid Tumours.
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
August 18, 2020
Completion date
October 7, 2024
Enrollment
60 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumours, cervical cancer, clear cell renal cell cancer, gastroesophageal cancer, melanoma, non-small-cell lung cancer, small cell lung cancer, squamous cell cancer of head and neck, triple negative breast neoplasms